SJVIA sees roughly 29% preliminary renewal increase; board directs staff to finalize plan and pursue controls

The San Joaquin Valley Insurance Authority board on Tuesday directed staff to finalize a preliminary 2027 renewal that consultants said would raise rates by about 29% overall, citing steep medical claims and concentrated pharmacy spending, particularly on GLP‑1 anti‑obesity medications.

"When we looked at the projections for the renewal, they're coming in higher than we expected," said Joy Giblin, a consultant with USI. She summarized the preliminary number as a 29.2% overall increase for the SJVIA plans (29.1% for Fresno and 29.3% for Tulare). The board voted unanimously to give staff direction to complete the renewal and return final recommendations in August.

Giblin and Bill Hernandez, USI's senior consulting underwriter, told the board the increase reflects recent claims experience: membership and per‑member claims trends produced an estimated $95 million in annual claims for one county's book of business and an overall budget figure far higher than current fully insured equivalents. Hernandez reported per‑member‑per‑month figures of about $517 for medical and $222 for pharmacy after stop‑loss adjustments and said the projected total budget approaches $102 million for the program period under review.

Consultants and the SJVIA pharmacy team identified GLP‑1 drugs — the class that includes anti‑obesity products such as Wegovy and Zepbound — as a concentrated driver of pharmacy costs. "AOMs alone represent 23% of your total pharmacy spend," said Jess Williams, the SJVIA pharmacy consultant, noting the plan's pharmacy program was tracking near $40 million annually (about $235 PMPM before rebates).

Presenters outlined a menu of mitigation strategies rather than a single prescription. Options discussed included enhanced prior authorization and stricter clinical criteria, specialty tiers or higher member cost share for anti‑obesity GLP‑1 products, pairing medication coverage with structured weight‑management programs, evaluating oral GLP‑1 alternatives, and pursuing direct‑to‑employer or direct‑to‑consumer purchasing models and HRAs to lower net cost exposure.

Giblin cautioned that a pending manufacturer price change will not automatically translate to savings because rebates could decline as list prices fall. "We believe it'll have an impact to rebates because the costs are lower, so we don't know what the net net savings is gonna be as of yet," she said. Consultants said they will seek a gross‑to‑net analysis from the PBM and project 2027 net impacts before the final renewal.

Board members pressed staff for decisive action. "If we as an entity have to drive change because of these costs, we've got to do that because this is not sustainable for the entity, and it's not sustainable for our employees," one committee member said. A labor representative during public comment called a 29% increase "unsustainable" and urged collaboration with labor groups on acceptable solutions.

The board's motion directed staff to finalize the renewal and pursue the mitigation measures described; the motion passed unanimously by voice vote. Consultants said they expect to return a final renewal in August, with detailed recommendations on plan‑design changes, stop‑loss options and PBM configuration checks.

Votes at a glance

- Item 8 (retroactive appropriations transfer and $7,000,000 appropriation increase to cover FY2026 shortfalls): approved unanimously on voice vote. Notes: exact roll‑call counts not specified in the transcript.

- Item 13 (direction to staff to finalize the preliminary 2027 renewal and pursue mitigation options): motion to approve staff direction carried unanimously on voice vote. Notes: exact roll‑call counts not specified in the transcript.

What happens next

USI and the SJVIA pharmacy team will analyze PBM and rebate impacts, model net effects of the announced manufacturer price change, and return with a final renewal recommendation and budget implications at the August meeting.